6 Surprising Revelations About Medicare's Alzheimer's Drug Spending Forecast

When Medicare's actuaries crunched the numbers two years ago, they painted a clear picture: the new Alzheimer's drug Leqembi would cost the program a staggering $3.5 billion by 2025. Fast forward to today, and that prediction has turned into a cautionary tale about the uncertainties of healthcare forecasting. This listicle unpacks the key factors behind the miss and what it means for patients, taxpayers, and the future of Alzheimer's treatments.

1. The Initial Prediction Was Massive

In 2023, Medicare's Office of the Actuary projected that Leqembi, a groundbreaking Alzheimer's therapy from Eisai and Biogen, would add $3.5 billion to program spending by 2025. This figure was based on assumptions of rapid uptake, high list prices, and broad patient eligibility. The prediction sent shockwaves through policy circles, sparking debates about drug pricing and budget impacts. Yet, as we now know, the reality has been far different—Leqembi's actual costs have been a fraction of that estimate, raising questions about the reliability of such forecasts and the factors that drive them.

2. Why the $3.5 Billion Forecast Missed the Mark

The prediction error stems from multiple miscalculations. First, actuaries overestimated how quickly Leqembi would be adopted by doctors and patients. The drug requires regular intravenous infusions and a confirmation of amyloid plaque in the brain, which slows enrollment. Second, Medicare's coverage decision imposed stringent requirements, including mandatory registry participation and safety monitoring, which dampened initial demand. Additionally, the high out-of-pocket costs for patients—despite some insurance coverage—discouraged many from starting treatment. These factors combined to create a slower-than-expected ramp, defying the original forecast.

3. The Slow Rollout of Leqembi

Leqembi's journey to market has been anything but smooth. After receiving accelerated FDA approval in early 2023, full approval came in July 2023, but only for patients with mild cognitive impairment. The narrow indication limited the eligible population, and many physicians hesitated to prescribe due to concerns over side effects like brain swelling and bleeding. Furthermore, the diagnostic process—requiring PET scans or spinal taps—added logistical hurdles. By late 2024, only a few thousand patients had started the drug, a far cry from the predicted hundreds of thousands. This snail-paced rollout is a primary reason Medicare's spending has remained below projections.

4. Medicare's Coverage Decision Complications

Medicare's coverage policy for Leqembi, issued in July 2023, was a game-changer—but not in the way actuaries expected. The Centers for Medicare & Medicaid Services (CMS) mandated that patients must be enrolled in a qualifying registry to track real-world outcomes. This added bureaucratic friction for doctors and hospitals, many of whom were not set up to participate. Additionally, CMS required continuous safety monitoring, which increased costs and complexity. While intended to gather data and protect patients, these requirements inadvertently suppressed demand, creating a self-fulfilling prophecy of lower utilization and spending.

5. The Real Cost to Patients and Taxpayers

Despite the lower-than-expected Medicare spending, the financial burden on patients has been significant. Leqembi's list price is around $26,500 per year, and even with Medicare coverage, copayments can reach thousands of dollars annually. For seniors with fixed incomes, these costs are prohibitive. Additionally, the drug's infusion administration costs, travel expenses, and time off work for caregivers add hidden expenses. Meanwhile, Medicare's actual spending in 2025 is likely to be under $500 million, far below the $3.5 billion projection. This disparity highlights the challenge of balancing affordability with access in the Alzheimer's treatment landscape.

6. What the Miss Means for Future Alzheimer's Drugs

The Leqembi prediction miss serves as a wake-up call for policymakers and drugmakers. It underscores the difficulty of forecasting demand for new therapies with narrow indications, complex administration, and high prices. Future Alzheimer's drugs, such as donanemab from Eli Lilly, may face similar hurdles unless these lessons are heeded. Improved patient education, streamlined coverage criteria, and innovative pricing models could help accelerate uptake. For now, Medicare's miss is a reminder that even the best models can be humbled by real-world dynamics—and that the path to treating Alzheimer's is as much about logistics as it is about science.

In conclusion, Medicare's wildly off-target forecast for Leqembi spending reveals the intricate interplay between drug access, pricing, and policy. While the lower costs may ease taxpayer burden temporarily, the slow adoption of effective Alzheimer's treatments remains a public health concern. As new therapies emerge, stakeholders must collaborate to refine forecasting methods and remove barriers to care—ensuring that patients don't get lost in the numbers.